135-LB: Cost Effectiveness of the FreeStyle Libre System vs. Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Treatment Not Reaching Glycemic Goals in Sweden

Abstract

A long-term health economic analysis was performed in Sweden to establish the cost-effectiveness of the FreeStyle Libre® system versus SMBG in T2D insulin treated patients not reaching their glycemic goals. The analysis used the IQVIA Core Diabetes Model. Baseline patients’ characteristics and HbA1c data were sourced from the recent real-world study using the Swedish National Diabetes Registry combined with hypoglycemia rates from the REPLACE trial. Simulations were performed in 2 different populations, those with HbA1c ≥8-9% (64-75 mmol/mol) and those with HbA1c ≥9-12% (75-108 mmol/mol), that went along with different treatment effects for FreeStyle Libre users (-0.41% and -1.30% HbA1c reduction respectively), assuming no treatment effect for those continuing on SMBG. The analysis was performed from the societal perspective over a lifetime time horizon. The Cost-Effectiveness results are presented below. For Sweden-based patients with T2D on insulin not reaching glycemic goals, the FreeStyle Libre system is associated with improvements in clinical outcomes and seems, with the assumptions taken, a cost-effective disease management option relative to SMBG, based on a willingness-to-pay threshold of SEK 300,000 (USD 34,113) per QALY gained. Sensitivity and scenario analyses confirmed the robustness of the analysis.View largeDownload slideView largeDownload slide DisclosureJ. H. Jendle: Speaker’s Bureau; Self; Abbott Diabetes, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk, Sanofi. K. Eeg-olofsson: Other Relationship; Self; Abbott Diabetes, Sanofi. A. Svensson: None. S. Franzén: None. M. Lamotte: Employee; Self; IQVIA, Employee; Spouse/Partner; Janssen Pharmaceuticals, Inc., Other Relationship; Self; Abbott Diabetes, Boehringer Ingelheim International GmbH, Dexcom, Inc., Insulet Corporation, Lilly Diabetes, Medtronic, Novo Nordisk A/S, Sanofi. F. Levrat-guillen: Employee; Self; Abbott Laboratories.FundingAbbott Diabetes Care